Chroma Medicine

Cambridge, United States Founded: 2020 • Age: 6 yrs
Epigenetic editing platform is developed for genomic medicines.

About Chroma Medicine

Chroma Medicine is a Healthcare company based in Cambridge (United States) founded in 2020. Epigenetic editing platform is developed for genomic medicines. Chroma Medicine has raised $135 million across 3 funding rounds from investors including ARE, T. Rowe Price and Janus Henderson Investors. The company has 122 employees. Chroma Medicine has completed 1 acquisition, including Epsilen Bio. Its chief executive, as recorded, is Catherine Stehman Breen. Chroma Medicine offers products and services including Epigenetic Editors, DLVR Particles, and CRMA-1001. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include FOXO Technologies, Reaction Biology and Epinoma; 1 of its 3 listed competitors has raised funding.

Company details

Chroma Medicine was founded in 2020 and is based in Cambridge, United States. An epigenetic editing platform is developed by the company within the biotechnology sector, focusing on genomic medicines. Gene expression is modulated through precise targeting of the epigenome, without changes to the underlying DNA sequence. This approach is applied to address diseases driven by genetic factors, supporting operations in research and therapeutic development.

  • Headquarters Cambridge, United States
  • Employees 122
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website chromamedicine.com
  • Social LinkedIn X
Key Metrics
  • Total Equity Funding
    $135M (USD)

    in 3 rounds

  • Latest Funding Round
    $135M (USD), Series B

    Feb 2023

  • Investors
    ARE

    & 17 more

  • Employee Count
    122
  • Investments & Acquisitions

Products & Services of Chroma Medicine

Chroma Medicine offers a comprehensive portfolio of products and services, including Epigenetic Editors, DLVR Particles, and CRMA-1001.

Epigenetic Editors
Gene Regulation Tool

Enables one-time cures by regulating genes without DNA changes.

DLVR Particles
Delivery Technology

Facilitates efficient, cell-specific delivery of macromolecules for editing.

CRMA-1001
Therapeutic Candidate

Targets chronic hepatitis B for deep, durable gene silencing.

Funding Insights of Chroma Medicine

Chroma Medicine has successfully raised a total of $135M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $135M
  • Total Rounds 3
  • Last Round Series B β€” $135M
  • Investors Count 18

All 3 funding rounds of Chroma Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Feb 2023$135MSeries B–Google Ventures
Nov 2021Series A–Cormorant-asset
Jun 2020Seed–Newpath Partners, Atlas Venture
Valuation history

18 investors in total: 18 institutional.

Investors in Chroma Medicine

Chroma Medicine has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, T. Rowe Price and Janus Henderson Investors.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Corporate backed venture capital fund investing in multiple sectors
gv.comMountain View, United States
Venture capital firm focused on life science companies
1986archventure.comChicago, United States
Private equity and debt investments are managed across multiple sectors.
sixthstreet.comSan Francisco, United States
Biotech funding, drug development support, and investment in life sciences.
sofinnova.com
Venture capital firm investing in life science and biotechnology sectors
1980atlasventure.comCambridge, United States
Venture capital firm
omegafunds.comBoston, United States
Venture capital firm focused on multiple sectors
dcvc.comPalo Alto, United States
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
Multiple sectors are targeted for venture capital investments.
1934janushenderson.comLondon, United Kingdom
Investment management services are offered by Newpath Partners.
newpath.partnersBoston, United States
Premium access

Investor details for Chroma Medicine

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Chroma Medicine

26 people are tracked at Chroma Medicine (6 in leadership, 10 in board & advisors, 10 in team); the tracked headcount is 122.

NameRoleGroup
Catherine Stehman Breen
CEOLeadership
Sivan Harel
Director, Translational Biomarkers & BioanalyticsLeadership
Cecilia Fernandez
VP, Strategic Planning & OperationsLeadership
Tobias Brambrink
VP, Intellectual PropertyLeadership
Sahar Abubucker
VP, Data SciencesLeadership
Adam Connelly
Director Of Quality ControlLeadership
Howard Chang
AdvisorBoard & advisors
Luke Gilbert
FounderBoard & advisors
J. Keith Joung
FounderBoard & advisors
Jonathan Weissman
FounderBoard & advisors
Ahmad Khalil
AdvisorBoard & advisors
David Liu
FounderBoard & advisors
Angelo Lombardo
FounderBoard & advisors
Luigi Naldini
FounderBoard & advisors
Bradley Bernstein
AdvisorBoard & advisors
Paula Cannon
AdvisorBoard & advisors
Melissa Pannone
Associate Scientist ITeam
Kyle Runckel
Scientist IITeam
Hasit Lunagaria
SVP, People & CultureTeam
Lenka Kundrat Hoffman
Principal ScientistTeam

6 more people are available in the full profile.

Premium access

Complete people profiles for Chroma Medicine

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Chroma Medicine

Chroma Medicine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epsilen Bio.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Epigenetic gene silencing technologies are developed for disease treatments.
epsilenbio.comMilano, Italy2019Nov 2021β€’β€’β€’β€’
Premium access

Complete acquisition details for Chroma Medicine

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Chroma Medicine

4 dated milestones of Chroma Medicine across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Chroma Medicine is founded.
  2. Funding First funding round.
  3. Acquisition Acquires Epsilen Bio.
  4. Funding Latest funding round, Series B, of $135.0M.

Competitors of Chroma Medicine

Chroma Medicine has 3 listed competitors in our database, 1 of them funded. They include FOXO Technologies, Reaction Biology and Epinoma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
foxotechnologies.com2020Minneapolis, United States
Epigenetic biomarkers are discovered and developed via AI platforms.
reactionbiology.com2001United States77
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
epinoma.com2020San Carlos, United States$125,0004
Limited information available
Premium access

Detailed competitors of Chroma Medicine

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Chroma Medicine

Websites that share an audience with Chroma Medicine (chromamedicine.com).

Similar websites

Websites whose visitors overlap most with Chroma Medicine. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
cuebiopharma.com
100%
4.9K#7,063,180View details
sherlock.bio
97%
2.8K#4,929,420View details
lyndra.com
96%
#9,629,878View details
ornatx.com
95%
4.4K#3,250,511View details
dynotx.com
93%
14.4K#2,089,404View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 16 similar websites and full traffic analytics for Chroma Medicine

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 16 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Chroma Medicine (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Chroma Medicine

Premium access

Complete news archive for Chroma Medicine

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chroma Medicine

Chroma Medicine was founded in 2020.

Chroma Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Catherine Stehman Breen is the CEO of Chroma Medicine, as recorded in our data.

Chroma Medicine is a funded company, having raised a total of $135M across 3 funding rounds to date.

Chroma Medicine has 122 employees.

Chroma Medicine was founded in 2020 and is based in Cambridge, United States. An epigenetic editing platform is developed by the company within the biotechnology sector, focusing on genomic medicines. Gene expression is modulated through precise targeting of the epigenome, without changes to the underlying DNA sequence. This approach is applied to address diseases driven by genetic factors, supporting operations in research and therapeutic development.

Chroma Medicine's top competitors include FOXO Technologies, Reaction Biology and Epinoma.

Chroma Medicine offers Epigenetic Editors, DLVR Particles, and CRMA-1001.

Chroma Medicine has made 1 acquisition, including Epsilen Bio.

Chroma Medicine has 18 investors. Key investors include ARE, T. Rowe Price, Janus Henderson Investors, Arch Venture Partners, and Atlas Venture.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available